Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Files An 8-K Other Events
Item8.01. Other Events.
On December19, 2016, Tetraphase Pharmaceuticals,Inc. (the
Company), issued a press release announcing that, during the
second half of 2017, it plans to file a Marketing Authorization
Application to the European Medicines Agency for the intravenous
(IV) form of its antibiotic candidate eravacycline for the
treatment of complicated intra-abdominal infections. The Company
also announced that, during the first quarter of 2017, it plans
to initiate IGNITE3, a randomized, multi-center, double-blind,
phase 3 clinical trial evaluating the efficacy and safety of
once-daily IV eravacycline compared to ertapenem for the
treatment of complicated urinary tract infections.
A copy of the press release announcing these events has been
filed as Exhibit99.1 to this Current Report on Form8-K and is
incorporated herein by reference.
Item9.01. Financial Statements and Exhibits.
| (d) | Exhibits |
See Exhibit Index attached hereto.
About Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections. It has developed eravacycline using its chemistry technology. The Company’s TP-271 is a fully synthetic spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271, the Company has conducted a number of in vitro, toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens. It also develops TP-6076 for multidrug-resistant Gram- negative infections. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Recent Trading Information
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) closed its last trading session down -0.03 at 4.29 with 567,545 shares trading hands.